Morgan Stanley Aspira Women'S Health Inc. Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.32 - $0.58 $28,947 - $52,467	90,462 Added 174.88%	142,189 $52,000
Q4 2022 Feb 14, 2023	SELL	$0.3 - $0.41 $9,015 - $12,321	-30,052 Reduced 36.75%	51,727 $17,000
Q3 2022 Nov 14, 2022	SELL	$0.38 - $1.07 $29,090 - $81,912	-76,554 Reduced 48.35%	81,779 $31,000
Q2 2022 Oct 27, 2022	SELL	$0.4 - $1.09 $36,671 - $99,930	-91,679 Reduced 36.67%	158,333 $93,000
Q2 2022 Aug 15, 2022	SELL	$0.4 - $1.09 $36,671 - $99,930	-91,679 Reduced 36.67%	158,333 $93,000
Q1 2022 Oct 27, 2022	BUY	$0.88 - $1.81 $80,677 - $165,938	91,679 Added 57.9%	250,012 $259,000
Q1 2022 May 13, 2022	SELL	$0.88 - $1.81 $2.18 Million - $4.48 Million	-2,474,846 Reduced 90.82%	250,012 $259,000
Q4 2021 Feb 14, 2022	BUY	$1.63 - $3.43 $2.25 Million - $4.74 Million	1,380,875 Added 102.74%	2,724,858 $4.82 Million
Q3 2021 Nov 15, 2021	BUY	$3.19 - $5.48 $4.29 Million - $7.37 Million	1,343,983 New	1,343,983 $4.37 Million

431K

Ticker AWH
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 124,296,000
Market Cap $123M
Description
Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gyneco...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.